Antidepressants and breast and ovarian cancer risk: A review of the literature and researchers' financial associations with industry

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Cosgrove, Lisa ^a,b   Shi, Ling ^b   Creasey, David E ^b,c   Anaya McKivergan, Maria ^d   Myers, Jessica A ^e   Huybrechts, Krista F ^e  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PHOENIX   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CELL GROWTH; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CARCINOGENICITY; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; FEMALE; FINANCIAL MANAGEMENT; GENOTOXICITY; HUMAN; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; OVARY CANCER; REVIEW; RISK ASSESSMENT; SHORT COURSE THERAPY; TUMOR PROMOTION; BAYES THEOREM; BREAST TUMOR; ECONOMICS; INDUSTRY; OVARY TUMOR; PERSONNEL; PUBLISHING; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; BAYES THEOREM; BREAST NEOPLASMS; FEMALE; HUMANS; INDUSTRY; OVARIAN NEOPLASMS; PUBLICATION BIAS; RESEARCH PERSONNEL; RISK FACTORS;

EID: 79953763335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018210     Document Type: Review

References (95)

1. Cotterchio M, Kreiger N, Darlington G, Steingart A, (2000) Antidepressant medication and breast cancer risk. Am J Epidemiol 151: 951-957.
2. Kelly JP, Rosenberg L, Rao RS, Palmer JR, Shapiro S, (1998) Is use of antidepressants associated with the occurrence of breast cancer? Am J Epidemiol 147 (Suppl): S69.
3. Steingart AB, Cotterchio M, (1995) Do antidepressants cause, promote, or inhibit cancers? J Clin Epidemiol 48 (11): 1407-1412.
4. Harlow BL, Cramer DW, (1995) Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies. Cancer Causes Control 6 (2): 130-134.
5. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CLF, et al. (1992) Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52: 3796-3800.
6. Iishi H, Tatsuta M, Miyako B, Taniguchi H, (1993) Enhancement by the tricyclic antidepressant, desipramine, of experimental carcinogenesis in rat colon induced by azoxymethane. Carcinogenesis 14 (9): 1837-1840.
7. Yank V, Rennie D, Bero LA, (2007) Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 335 (7631): 1202-1205.
8. National Cancer Institute Surveillance and Epidemiology and End Results. Cancer Facts Sheets. Surveillance and Epidemiology and End Results (SEER). http://seer.cancer.gov/statfacts/html/breast.html. Accessed October 23, 2009.
9. American Cancer Society. Cancer: Basic Facts. American Cancer Society. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed October 23, 2009.
10. Olfson M, Marcus SC, (2009) National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66 (8): 848-856.
11. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Text rev Washington, DC Author.
12. Roberts H, (2007) Managing the menopause. BMJ 334 (7596): 736-741.
13. Hilakivi-Clarke L, Wright A, Lippman ME, (1993) DMBA-induced mammary tumor growth in rats exhibiting increased or decreased ability to cope with stress due to early postnatal handling or antidepressant treatment. Physiol Behav 54 (2): 229-236.
14. Spina E, Santoro V, D'Arrigo C, (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30 (7): 1206-1227.
15. Aubert RE, Stanek EJ, Yao J, Teagarden JR, Subar M, et al. (2009) Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 27 (18s): cra508.
16. Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S, (1982) Nonestrogenic drugs and breast cancer. Am J Epidemiol 116 (2): 329-332.
17. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, et al. (2001) Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 54 (7): 728-734.
18. Dublin S, Rossing MA, Heckbert SR, Goff BA, Weiss NA, (2002) Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control 13 (1): 35-45.
19. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL, (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282 (15): 1453-1457.
20. Angell M, (2004) The truth about drug companies: how they deceive us and what to do about it New York Random House.
21. Stelfox HT, Chua G, O'Rourke K, Detsky AS, (1998) Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338: 101-106.
22. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, et al. (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163 (2): 185-194.
23. Lawlor DA, Jüni P, Ebrahim E, Egger M, (2003) Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 56 (2): 155-163.
24. Steingart A, Cotterchio M, Kreiger N, Sloan M, (2003) Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 32 (6): 961-966.
25. Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, et al. (2006) Antidepressant use and breast cancer risk. Breast Cancer Res Treat 95 (2): 131-140.
26. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Stolley PD, et al. (2000) Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines. Cancer Causes Control 11 (9): 839-845.
27. Coogan PF, Palmer JR, Strom BL, Rosenberg L, (2005) Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 162 (9): 835-838.
28. Coogan PF, Strom BL, Rosenberg L, (2008) SSRI use and breast cancer risk by hormone receptor status. Breast Cancer Res Treat 109 (3): 527-531.
29. Dalton SO, Johansen C, Mellemkjaer L, Sorensen HT, McLaughlin JK, et al. (2000) Antidepressant medications and risk for cancer. Epidemiology 11 (2): 171-176.
30. González-Pérez A, García Rodríguez LA, (2005) Breast cancer risk among users of antidepressant medications. Epidemiology 16 (1): 101-105.
31. Haque R, Enger SM, Chen W, Petitti DB, (2005) Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett 221 (1): 61-65.
32. Harlow BL, Cramer DW, Baron JA, Titus-Ernstoff L, Greenberg ER, (1998) Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 7 (8): 697-702.
33. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, et al. (2000) Psychotropic medication use and risk of hormone related cancers: the New York University Women's Health Study. J Pub Health Med 22 (2): 155-160.
34. Moorman PG, Grubber JM, Millikan RC, Newman B, (2003) Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14 (3): 307-314.
35. Moorman PG, Berchuck A, Calingaert B, Halabi S, Schildkraut JM, (2005) Antidepressant medication use and risk of ovarian cancer. Obstet Gynecol 105 (4): 725-730.
36. Sharpe CR, Collet J-P, Belzile E, Hanley JA, Boivin J-F, (2002) The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 86 (1): 92-97.
37. Tamim H, Boivin J-F, Hanley J, Stang MR, Collet J-P, (2006) Risk of breast cancer in association with exposure to two different groups of tricyclic antidepressants. Pharmacoepidemiol Drug Saf 15 (10): 689-697.
38. Wallace RB, Sherman BM, Bean JA, (1982) A case-control study of breast cancer and psychotropic drug use. Oncology 39 (5): 279-283.
39. Weiss SR, McFarland BH, Burkhart GA, Ho PT, (1998) Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants. Clin Pharmacol Ther 63 (5): 594-599.
40. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA, (2009) Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf 18 (4): 284-290.
41. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, et al. (2010) Incidence of cancer and antidepressant medication: record linkage study. Int J Cancer 126 (1): 285-296.
42. Davis S, Mirick DK, (2007) Medication use and the risk of breast cancer. Eur J Epidemiol 22 (5): 319-325.
43. Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS, (2006) Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 94 (7): 1071-1078.
44. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7 (3): 177-188.
45. Abdul M, Logothetis CJ, Hoosein NM, (1995) Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154 (1): 247-250.
46. Basso AM, Depiante-Depaoli M, Molina VA, (1992) Chronic variable stress facilitates tumoral growth: reversal by imipramine administration. Life Sci 50 (23): 1789-1796.
47. Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM, (1992) Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 52: 6931-6935.
48. Brambilla G, Cavanna M, Faggin P, Pino A, Robbiano L, et al. (1982) Genotoxic activity of five antidepressant hydrazines in a battery of in vivo and in vitro short-term tests. J Toxicol Environ Health 9 (2): 287-303.
49. Clayson DB, Biancifiori C, Milia U, Santilli FEG, (1965) The induction of pulmonary tumors in BALB/c/Cb/Se mice by derivatives of hydrazine. In: Severi L, editors. Lung tumours in animals: Proceedings of the third quadrennial conference on cancer Perugia Division of Cancer Research pp. 869-80.
50. Frick LR, Palumbo ML, Zappia MP, Brocco MA, Cremaschi GA, et al. (2008) Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. Biochem Pharmacol 75 (9): 1817-1826.
51. Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, et al. (2008) Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol 33 (2): 277-286.
52. Jia L, Shang Y-Y, Li Y-Y, (2008) Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol 14 (27): 4377-4382.
53. Kelvin AS, Mitchell ID, White DJ, (1989) General and genetic toxicology of paroxetine. Acta Psychiatr Scand Suppl 350: 34-36.
54. Merry S, Hamilton TG, Flanigan P, Freshney RI, Kaye SB, (1991) Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur J Cancer 27 (1): 31-4.
55. Sauter C, (1989) Cytostatic activity of commonly used tricyclic antidepressants. Oncology 46 (3): 155-157.
56. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, et al. (2003) Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101 (8): 3212-3219.
57. Shoyab M, Todaro GJ, Tallman JF, (1982) Chlorpromazine and related antipsychotic tricyclic compounds competitively inhibit the interaction between tumor-promoting phorbol esters and their specific receptors. Cancer Lett 16 (2): 171-177.
58. Slamon ND, Ward TH, Butler J, Pentreath VW, (2001) Assessment of DNA damage in C6 glioma cells after antidepressant treatment using an alkaline comet assay. Arch Toxicol 75 (4): 243-250.
59. Sonier B, Arseneault M, Lavigne C, Ouellette RJ, Vaillancourt C, (2006) The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophysical Res Comm 343 (4): 1053-1059.
60. Toth B, (1975) Synthetic and naturally occurring hydrazines as possible cancer causative agents. Cancer Res 35: 3693-3697.
61. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y, (1982) Potentiation of chemotherapeutic effect of vincristine in vincristine resistant tumor bearing mice by calmodulin inhibitor clomipramine. J Pharmacobiodyn 6 (2): 145-147.
62. Tucker WE Jr, (1983) Preclinical toxicology of bupropion: an overview. J Clin Psychiatry 44 (5 Pt 2): 60-62.
63. Tutton PJ, Barkla DH, (1976) A comparison of cell proliferation in normal and neoplastic intestinal epithelia following either biogenic amine depletion or monoamine oxidase inhibition. Virchows Arch B Cell Pathol 21 (1): 161-168.
64. Tutton PJ, Barkla DH, (1982) Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. Br J Cancer 46 (2): 260-265.
65. Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ, (2003) Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Ther Oncol 3 (4): 169-184.
66. Wright SC, Zhong J, Larrick JW, (1994) Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 8 (9): 654-660.
67. Rosetti M, Frasnelli M, Tesei A, Zoli W, Conti M, (2006) Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. J Exp Ther Oncol 6 (1): 23-29.
68. Arimochi H, Morita K, (2008) Desipramine induces apoptotic cell death through nonmitochondrial and mitochondrial pathways in different types of human colon carcinoma cells. Pharmacology 81 (2): 164-172.
69. Xia Z, Bergstrand A, DePierre JW, Nässberger L, (1999) The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol 13 (6): 338-347.
70. Chou C-T, He S, Jan C-R, (2007) Paroxetine-induced apoptosis in human osteosarcoma cells: activation of p38 MAP kinase and caspase-3 pathways without involvement of [Ca2+]i elevation. Toxicol Appl Pharmacol 218 (3): 265-273.
71. Stepulak A, Rzeski W, Sifringer M, Brocke K, Gratopp A, et al. (2008) Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther 7 (10): 1685-1693.
72. Spanová A, Kovárů H, Lisá V, Lukásová E, Rittich B, (1997) Estimation of apoptosis in C6 glioma cells treated with antidepressants. Physiol Res 46 (2): 161-164.
73. Cloonan SM, Drozgowska A, Fayne D, Williams DC, (2010) The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk Lymphoma 51 (3): 523-539.
74. Lee CS, Kim YJ, Jang ER, Kim W, Myung SC, (2009) Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-jB. Basic Clin Pharmacol Toxicol 106: 446-453.
75. Lin C-J, Robert F, Sukarieh R, Michnick S, Pelletier J, (2010) The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling. Cancer Res 70 (8): 3199-3208.
76. Brandes LJ, (2005) Hormetic effects of hormones, antihormones, and antidepressants on cancer cell growth in culture: in vivo correlates. Crit Rev Toxicol 35 (6): 587-592.
77. Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L, (2006) Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychsom 75 (3): 154-160.
78. Cosgrove L, Bursztajn H, Krimsky S, Anaya M, Walker J, (2009) Conflicts of interest and disclosure in the American Psychiatric Association's clinical practice guidelines. Psychother Psychsom 78 (4): 228-232.
79. Spiegel D, Giese-Davis J, (2003) Depression and cancer: mechanisms and disease progression. Biol Psych 54 (3): 269-82.
80. Calabrese EJ, (2005) Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol 35 (6): 463-582.
81. Calabrese EJ, Baldwin LA, (2001) U-shaped dose-responses in biology, toxicology, and public health. Annu Rev Public Health 22: 15-33.
82. Bekelman JE, Li Y, Gross CP, (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289 (4): 454-465.
83. Smith R, (2005) Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2 (5): e138.
84. Angell M, (2000) Is academic medicine for sale? N Engl J Med 342: 1516-1518.
85. Brown WR, (1991) Implication of the reexamination of the liver sections from the TCDD chronic rat bioassay. In: Gallo M, Scheuplein J, Van der Heijden KA, editors. Biological basis for risk assessment of dioxins and related compounds Cold Spring Harbor, NY Cold Spring Harbor Laboratory Press pp. 13-28.
86. Douglas H, (2000) Inductive risk and values in science. Philos Sci 67: 559-579.
87. Douglas H, (2007) Rejecting the ideal of value-free science. In: Kincaid H, Dupré J, Wylie A, editors. Value-free science?: ideals and illusions New York, NY Oxford University Press pp. 120-140.
88. Fugh-Berman A, (2005) The corporate coauthor. J Gen Intern Med 20 (6): 546-548.
89. Rising K, Bacchetti P, Bero L, (2008) Reporting bias in drug trials submitted to the Food and Drug Administration: a review of publication and presentation. PLoS Med 5 (11): e217.
90. Sheldon T, (2005) Focus on the funding and production of evidence rather than its publication. PLoS Med 2 (7): e222.
91. Thompson DF, (2009) The challenge of conflict of interest in medicine. Z Evid Fortbild Qual Gesundhwes 103: 136-140.
92. Falit BP, (2007) Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. Seton Hall Law Rev 37 (4): 969-1049.
93. U.S. Preventive Services Task Force (2002) Screening for breast cancer: recommendations and rationale. Ann Intern Med 137 (5): 344-346.
94. Dunikowski LG, (2005) EMBASE and MEDLINE searches. Can Fam Physician 51 (9): 1191.
95. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, et al. (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340: c693.